{"id":12033,"date":"2013-10-31T11:32:08","date_gmt":"2013-10-31T15:32:08","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=12033"},"modified":"2013-10-31T11:32:08","modified_gmt":"2013-10-31T15:32:08","slug":"oxygen-biotherapeutics-inc-nasdaqoxbt-buying-certain-assets-from-phyxius-pharma","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbt-buying-certain-assets-from-phyxius-pharma-12033","title":{"rendered":"Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) buying certain assets from Phyxius Pharma"},"content":{"rendered":"<p style=\"text-align: justify;\">Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) which is a well known developer of oxygen-carrying therapeutics, has recently announced that it has signed a definitive agreement to take over some assets of Phyxius Pharma, which is a private biopharmaceutical company. OXBT will acquire exclusive rights to produce and sell Levosimendan in North America; it will also acquire three key executives from Phyxius Pharma into its own management team.\u00a0 The transaction which is estimated to at around $4.8 million in stocks and is based on Oxygen Biotherapeutics issuing at least 3.4 million shares of the common stock and securities to Phyxius Pharma as convertible common stock in a private placement.<\/p>\n<p style=\"text-align: justify;\">Post the transcation the Co-Founder and CEO of Phyxius Pharma will become the CEO of Oxyen Biotherapeutics and the current interim CEO of OXBT who is also the CFO, Michael Jebsen will step down but he will continue in his position as the CFO of the company.<br \/>\nLevosimendan\u00a0 is a drug that is used to treat acute decompensated heart failure and is approved in at least 53 countries. It is licensed originally from a Finland based Orion Corporation which is one of the global healthcare giants.<\/p>\n<p style=\"text-align: justify;\">This purchase will give OXBT the exclusive rights to Levosimendan, its development and commercialization in North America. Specifically the company has plans to use this drug to prevent and help treat low cardiac output syndrome, in addition to this it is also seeking FDA approval of Fast Track status for its Phase III trials.<\/p>\n<p style=\"text-align: justify;\">Interim CEO and CFO of Oxygen Biotherapeutics Michael Jebsen said that post this transaction Oxygen Biotherapeutics will have a clear path of entry into the potential market of $600 million with a Phase 3 asset. He also said that with the Fast Track Status that was awarded and a Special Protocol Assessment allowing an agreed study, the drug could be just one trial away from being approved.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) which is a well known developer of oxygen-carrying therapeutics, has recently announced that it has signed a definitive agreement to take [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":10910,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[2332,3999,2331],"stock_ticker":[],"class_list":["post-12033","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-nasdaqoxbt","tag-oxygen-biotherapeutics-inc","tag-oxygen-biotherapeutics-inc-nasdaqoxbt","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) buying certain assets from Phyxius Pharma - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbt-buying-certain-assets-from-phyxius-pharma-12033\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) buying certain assets from Phyxius Pharma - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) which is a well known developer of oxygen-carrying therapeutics, has recently announced that it has signed a definitive agreement to take [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbt-buying-certain-assets-from-phyxius-pharma-12033\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2013-10-31T15:32:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/554.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Brendan Byrne\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Brendan Byrne\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbt-buying-certain-assets-from-phyxius-pharma-12033#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbt-buying-certain-assets-from-phyxius-pharma-12033\"},\"author\":{\"name\":\"Brendan Byrne\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511\"},\"headline\":\"Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) buying certain assets from Phyxius Pharma\",\"datePublished\":\"2013-10-31T15:32:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbt-buying-certain-assets-from-phyxius-pharma-12033\"},\"wordCount\":320,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbt-buying-certain-assets-from-phyxius-pharma-12033#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/554.jpg\",\"keywords\":[\"NASDAQ:OXBT\",\"Oxygen Biotherapeutics Inc.\",\"Oxygen Biotherapeutics Inc. (NASDAQ:OXBT)\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbt-buying-certain-assets-from-phyxius-pharma-12033#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbt-buying-certain-assets-from-phyxius-pharma-12033\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbt-buying-certain-assets-from-phyxius-pharma-12033\",\"name\":\"Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) buying certain assets from Phyxius Pharma - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbt-buying-certain-assets-from-phyxius-pharma-12033#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbt-buying-certain-assets-from-phyxius-pharma-12033#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/554.jpg\",\"datePublished\":\"2013-10-31T15:32:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbt-buying-certain-assets-from-phyxius-pharma-12033#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbt-buying-certain-assets-from-phyxius-pharma-12033\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbt-buying-certain-assets-from-phyxius-pharma-12033#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/554.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/554.jpg\",\"width\":1024,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbt-buying-certain-assets-from-phyxius-pharma-12033#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) buying certain assets from Phyxius Pharma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511\",\"name\":\"Brendan Byrne\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g\",\"caption\":\"Brendan Byrne\"},\"description\":\"While studying economics, Brendan found himself comfortably falling down the rabbit hole of restaurant work, ultimately opening a consulting business and working as a private wine buyer. On a whim, he moved to China, and in his first week following a triumphant pub quiz victory, he found himself bleeding on the floor based on his arrogance. The same man who put him there offered him a job lecturing for the University of Wales in various sister universities throughout the Middle Kingdom. While primarily lecturing in descriptive and comparative statistics, Brendan simultaneously earned an Msc in Banking and International Finance from the University of Wales-Bangor. He's presently doing something he hates, respecting French people. Well, two, his wife and her mother in the lovely town of Antigua, Guatemala. You may contact Brendan via his email (brendanbyrne@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/u\/0\/116608759701551457422).\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/brendan-byrne\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) buying certain assets from Phyxius Pharma - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbt-buying-certain-assets-from-phyxius-pharma-12033","og_locale":"en_US","og_type":"article","og_title":"Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) buying certain assets from Phyxius Pharma - Wall Street PR","og_description":"Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) which is a well known developer of oxygen-carrying therapeutics, has recently announced that it has signed a definitive agreement to take [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbt-buying-certain-assets-from-phyxius-pharma-12033","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2013-10-31T15:32:08+00:00","og_image":[{"width":1024,"height":768,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/554.jpg","type":"image\/jpeg"}],"author":"Brendan Byrne","twitter_misc":{"Written by":"Brendan Byrne","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbt-buying-certain-assets-from-phyxius-pharma-12033#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbt-buying-certain-assets-from-phyxius-pharma-12033"},"author":{"name":"Brendan Byrne","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511"},"headline":"Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) buying certain assets from Phyxius Pharma","datePublished":"2013-10-31T15:32:08+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbt-buying-certain-assets-from-phyxius-pharma-12033"},"wordCount":320,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbt-buying-certain-assets-from-phyxius-pharma-12033#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/554.jpg","keywords":["NASDAQ:OXBT","Oxygen Biotherapeutics Inc.","Oxygen Biotherapeutics Inc. (NASDAQ:OXBT)"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbt-buying-certain-assets-from-phyxius-pharma-12033#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbt-buying-certain-assets-from-phyxius-pharma-12033","url":"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbt-buying-certain-assets-from-phyxius-pharma-12033","name":"Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) buying certain assets from Phyxius Pharma - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbt-buying-certain-assets-from-phyxius-pharma-12033#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbt-buying-certain-assets-from-phyxius-pharma-12033#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/554.jpg","datePublished":"2013-10-31T15:32:08+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbt-buying-certain-assets-from-phyxius-pharma-12033#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbt-buying-certain-assets-from-phyxius-pharma-12033"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbt-buying-certain-assets-from-phyxius-pharma-12033#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/554.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/554.jpg","width":1024,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/oxygen-biotherapeutics-inc-nasdaqoxbt-buying-certain-assets-from-phyxius-pharma-12033#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) buying certain assets from Phyxius Pharma"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511","name":"Brendan Byrne","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g","caption":"Brendan Byrne"},"description":"While studying economics, Brendan found himself comfortably falling down the rabbit hole of restaurant work, ultimately opening a consulting business and working as a private wine buyer. On a whim, he moved to China, and in his first week following a triumphant pub quiz victory, he found himself bleeding on the floor based on his arrogance. The same man who put him there offered him a job lecturing for the University of Wales in various sister universities throughout the Middle Kingdom. While primarily lecturing in descriptive and comparative statistics, Brendan simultaneously earned an Msc in Banking and International Finance from the University of Wales-Bangor. He's presently doing something he hates, respecting French people. Well, two, his wife and her mother in the lovely town of Antigua, Guatemala. You may contact Brendan via his email (brendanbyrne@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/u\/0\/116608759701551457422).","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/brendan-byrne"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/12033","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=12033"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/12033\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/10910"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=12033"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=12033"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=12033"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=12033"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}